Product
Riliprubart
Aliases
SAR445088
1 clinical trial
4 indications
Indication
PolyneuropathyIndication
Inflammatory DemyelinatingIndication
ChronicClinical trial
A Phase 3, Doubleblind, Placebocontrolled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating PolyneuropathyStatus: Recruiting, Estimated PCD: 2026-02-03